Brynjelsen Sean's Form 4 filing
Eton Pharmaceuticals, Inc. (ETON) · filed Jun 5, 2025
- Accession no.
- 0001437749-25-019583
- Filed
- Jun 5, 2025
- Trade date
- Jun 3-5, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 0 derivative transactions. Open-market sales total $3.59M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Brynjelsen SeanCIK 0001669976 | Director, Officer (President & CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 3, 2025 | Common Stock | SSaleDisposed | −60,945 | $17.38 | −$1,059,224.1 | 3,022,568 | Direct | |
| Jun 3, 2025 | Common Stock | SSaleDisposed | −8,655 | $18.38 | −$159,078.9 | 3,013,913 | Direct | |
| Jun 3, 2025 | Common Stock | SSaleDisposed | −400 | $19.02 | −$7,608 | 3,013,513 | Direct | |
| Jun 4, 2025 | Common Stock | SSaleDisposed | −70,000 | $17.00 | −$1,190,000 | 2,943,513 | Direct | |
| Jun 5, 2025 | Common Stock | SSaleDisposed | −70,000 | $16.81 | −$1,176,700 | 2,873,513 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.